AG
BEAM icon

Algert Global’s Beam Therapeutics BEAM Stock Holding History

Algert Global’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.92M Buy
164,292
+130,002
+379% +$3.61M 0.06% 508
2025
Q4 		$951K Buy
+34,290
New +$875K 0.01% 858
2025
Q1 		– Sell
-9,378
Closed -$233K – 1186
2024
Q4 		$233K Sell
9,378
-34,145
-78% -$871K 0.01% 1050
2024
Q3 		$1.07M Buy
43,523
+32,130
+282% +$830K 0.03% 735
2024
Q2 		$267K Buy
+11,393
New +$280K 0.01% 1166

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Algert Global's BEAM Position: Q1 2026 in Review

Algert Global increased its Beam Therapeutics (BEAM) stake by 379% in Q1 2026, buying an estimated $3.61M and bringing the position to 164,292 shares worth $3.92M. The position accounts for 0.06% of the portfolio, ranked #508.

Algert Global first reported a position in BEAM in Q2 2024 and has held it in 5 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Algert Global held 164,292 shares of Beam Therapeutics worth $3.92M as of Q1 2026.
  • Algert Global bought 130,002 Beam Therapeutics shares in Q1 2026, an estimated $3.61M.
  • Beam Therapeutics made up 0.06% of Algert Global's portfolio in Q1 2026, its #508 holding.
  • Algert Global first reported a position in Beam Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.